You don't know how to read! You wrong on both of your assertions. There was statistically significant results (PFS) and they did live longer (but could not be shown statistically - that could change as they coontinue to follow the living patients).
sure OS is better, but PFS has been enough in cases of bad cancers to gain FDA approval without an improvement in OS. There is still real hope for the future of ICT-107, although I was hoping for better results - this may still be adequate for eventual FDA approval. On top of this, if the tail is long then the median survial could be moved if the remaining 57 live patients enrolled survive longer over the next several months or years.